Drug intelligence / Profile preview

heptaminol + deanol pidolate

Development stage: Phase 3
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Oral

Overview

DC158AM is an oral combination drug developed by Pierre Fabre Médicament, consisting of heptaminol hydrochloride and deanol pyroglutamate (also known as deanol pidolate). Heptaminol is a sympathomimetic amine that acts as a cardiovascular stimulant and anti-asthenic agent, while deanol pyroglutamate serves as a precursor to acetylcholine and acts as a nootropic. Historically marketed under brand names like Debrumyl and Denubil for the symptomatic treatment of general fatigue and asthenia, the combination is currently being evaluated in Phase 3 clinical trials for the treatment of fatigue in patients with Parkinson's disease.

Brand names: DebrumylDenubil
Other names: heptaminol hydrochloride + deanol pyroglutamateheptaminol hydrochloride + deanol pidolate

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on heptaminol + deanol pidolate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on heptaminol + deanol pidolate.